VANCOUVER, British Columbia, May 5, 2005 (PRIMEZONE) -- ProteoCell Biotechnologies Laboratory announces further positive results using synthetic AFGP in blood platelet preservation. Platelet integrity was monitored over a period extending to 21-days. The study observed AFGP effect at 4-temperatures starting at 22 C degrees, down to 15 C degrees, 4 C degrees and finally 0 C degrees. Two concentrations of AFGP (1mg./ml and 4mg./ml) were used in addition to the negative control without AFGP. Aggregation is one of the primary and most definitive indicators of platelet degradation.
The scientists at ProteoCell report a distinct correlation between the presence of AFGP and the lack of platelet aggregation. "As time progressed into days 13, 17 and 21, we find a marked difference and observable aggregation inhibition by AFGP," Samer Hussein, lead scientist for ProteoCell states. "That as time went on there is a very significant few hundred percent increase in aggregation counts in the negative control (without AFGP) relative to platelets in the presence of AFGP." The results clearly indicate that blood platelets treated with AFGP are healthier over time with less aggregation.
After 21-days of evaluation, the structural integrity of blood platelets was vastly superior to the untreated platelets. These findings strengthen ProtoKinetix' belief in the use of synthetic AFGP as a commercial blood platelet preservative to extend the present shelf life.
About ProtoKinetix:
ProtoKinetix, Inc. (OTCBB:PKTX) is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President